24 May 2013
Keywords: Merck KGaA, Cilengitide, Ph III, Glioblastoma
Article | 25 February 2013
German drug major Merck KGaA (MRK: DE) revealed this morning that the Phase III CENTRIC trial of the investigational integrin ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 February 2013
23 May 2013
© 2013 thepharmaletter.com